So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, castration-resistant, consensus, hormone-naive, hormone-sensitive, mCRPC, metastatic, mHSPC, nmCRPC, nmHSPC, non-metastatic | 2 Comments »
Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: enzalutamide, hormone-sensitive, HSPC, metastatic, Xtandi | 3 Comments »
The randomized, double-blind, Phase III ENZAMET trial was designed to investigate whether the combination of enzalutamide + standard androgen suppression had superior outcomes than a non-steroidal antiandrogen + standard androgen suppression in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, enzalutamide, ENZAMET, hormone-sensitive, metastatic, mHSPC, non-steroidal, overall, survival | 15 Comments »
At the end of January, we had reported that the results of the TITAN trial — the Phase III trial of standard ADT + apalutamide (Erlead) or standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer (mHSPC) — were positive, and that they were going to be reported at a meeting later in the year. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: apalutamide, Erleada, hormone-sensitive, metastatic, mHSPC | 12 Comments »
The results of the 1,125-patient, randomized, double-blind ENZAMET trial are to be reported in a late-breaking abstract at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ENZAMET, enzlutamide, hormone-sensitive, latitude, metastatic, mHSPC, outcome | 9 Comments »
Long-term follow-up data from the LATITUDE trial have now been published by Fizazi et al. in Lancet Oncology. … READ MORE …
Filed under: Uncategorized | Tagged: "high risk", abiraterone, ADT, hormone-sensitive, latitude, metastatic, newly diagnosed, survival | 4 Comments »
On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …
Filed under: Uncategorized | Tagged: ADT, ARCHES, enzalutamide, hormone-sensitive, metastatic, mHSPC, Xtandi | 4 Comments »
If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.
Our most recent CureTalk on Prostate Cancer (on February 21 this year) features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.
For access to the full list of CureTalks on Prostate Cancer, please click here.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
